This study is a post-market clinical follow-up (PMCF) plan for the StypCel™ Absorbable Hemostat, a medical device used to control bleeding during neurosurgery. The study include 108 patients . The aim of the study is to furtherly assess the safety and performance of the device under the real-word setting
The StypCel™ Absorbable Hemostat is designed to control bleeding during neurosurgical procedures. This PMCF study is an observational, multicenter study included 108 patients .Primary goal is to evaluate the device's ability to achieve hemostasis within 5 minutes during surgery. Secondary objectives include monitoring the rate of intracranial infections and other serious adverse events over 6 months. Data from the study will be collected at two-time points: 10 days and 180 days after the surgery, with follow-up assessments to monitor any delayed complications. These summaries are written in plain language, ensuring they are accessible to non-specialists while still providing essential information about the study's objectives, methodology, and expected outcomes.
Study Type
OBSERVATIONAL
Enrollment
108
Riga's East Clinical University Hospital Riga, Latvia
Riga, Latvia
Time to Hemostasis within 5 mins
The primary outcome is the time taken to achieve complete hemostasis at the surgical site after applying the StypCel™ Absorbable Hemostat during neurosurgery.
Time frame: during surgery (typically within 5 minutes)
Time to Hemostasis
Time to Hemostasis within 5 minutes
Time frame: During surgery
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.